BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Volumn 9, Issue 3, 2003, Pages 177-182

  Cooney, Julian P ^a   Stiff, Patrick J ^a   Toor, Amir A ^a   Parthasarathy, Mala ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEAM REGIMEN; CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN;

ADULT; ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT SURVIVAL; HODGKIN DISEASE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDY; REMISSION; SALVAGE THERAPY; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CARMUSTINE; CYTARABINE; ETOPOSIDE; FEMALE; GRAFT SURVIVAL; HODGKIN DISEASE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0642369739     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(03)70007-X     Document Type: Article

References (0)